FDA Panel Won't Back J&J's Xarelto For ACS Patients
In a 6-4 decision, a U.S. Food and Drug Administration advisory committee on Wednesday recommended against approving Johnson & Johnson and Bayer AG blood thinner Xarelto for patients with acute coronary...To view the full article, register now.
Already a subscriber? Click here to view full article